What is ALS Phase 3 Study VITALITY-ALS?
CATEGORY:
The ALS Phase 3 Study VITALITY-ALS clinical trial is examining the safety, tolerability and efficacy of tirasemtiv in patients with ALS. The clinical trial number is NCT02496767.
Save up to 80% off your prescriptions!
How do members experience ALS Phase 3 Study VITALITY-ALS?
Top 5 reported purposes & perceived effectiveness
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Amyotrophic lateral sclerosis | 8 | 21 | |
| Improve flexibility/strength | 5 | 20 | |
| Decreased diaphragm strength | 1 | 0 | |
| Diaphragm spasms | 1 | 0 |
Common side effects
| Side effect | Patients | Percentage |
|---|---|---|
| Dizziness | 3 | |
| Fatigue | 3 | |
| Constipation | 1 | |
| Drowsiness | 1 | |
| Irritability | 1 | |
| Jittery feeling | 1 |
Side effect severity
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 1 | |
| Moderate | 5 | |
| Mild | 12 | |
| None | 16 |
Learn more about our community’s experience with ALS Phase 3 Study VITALITY-ALS
What are people saying about ALS Phase 3 Study VITALITY-ALS?
25
25
members have reported taking ALS Phase 3 Study VITALITY-ALS
Join the conversation and connect with people who have taken ALS Phase 3 Study VITALITY-ALS
Last updated: